(Q51246122)
Statements
Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. (English)
1 reference
1 reference
H Ballentine Carter
1 reference
1 March 2013
1 reference
11
1 reference
3
1 reference
281-285
1 reference